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Summary 
Passive  Heymann nephritis (pHN) is an experimental rat model for human membranous glo- 
merulopathy. In pHN, the formation of subepithelial immune deposits (ID) involves as anti- 
genic targets the membrane glycoprotein gp330/megalin and the 44-kD receptor-associated 
protein (RAP). A single binding site for ID-inducing antibodies (Abs) was previously mapped 
to the 86 NH2-terminal amino acids  of RAP (P,_AP>86). To further narrow this epitope, Abs 
eluted from the glomeruli were immunoblotted on membranes that were loaded with overlap- 
ping synthetic peptides representing the amino acid sequence of RAP  (SPOTs system). Two 
adjacent Ab-binding domains with the sequences PVRLAE  (amino acids  39-44)  and HSD- 
LKIQE (amino acids  46-53),  which were separated by a single  L residue at amino acid 45, 
were detected. Rabbit Abs raised against  synthetic peptides containing these domains individu- 
ally (P31-44 and P46-53) failed to produce glomerular IDs. By contrast, Abs raised against  a larger 
composite peptide (P31-53) induced IDs within 3 d that were firmly cross-linked to the glomer- 
ular basement membrane. These data suggest that Ab binding in vivo depends on the confor- 
mation of the antigenic target sequence that is preserved in the synthetic peptide P31-53, which 
covers the entire Ab-binding domain of RAP but not in its subdomains, P31-44 and P46-53. Col- 
lectively, these results locate the sole ID-inducing epitope of RAP to amino acids 39-53. 
T 
he design of therapies for autoimmune diseases is pri- 
marily based on identification of antigenic targets and 
induction of specific immune tolerance. Considerable prog- 
ress has been made recently in several areas, such as allergic 
encephalomyelitis, in which  epitopes were identified and 
duplicated by synthetic peptides (1, 2). However, relatively 
little is known about antigens ofglomerular immune com- 
plex diseases  despite their tendency to cause chronic renal 
failure. To learn more about the molecular pathogenesis of 
one relatively frequent glomerular immune disease,  mem- 
branous glomerulopathy (3), we have investigated in detail 
an established experimental model in rats, i.e., passive Hey- 
mann nephritis  (pHN) 1 (4,  5).  A  hallmark of pHN is the 
presence of granular  subepitheliaI immune  deposits  (IDs) 
that firmly adhere to the glomemlar basement membrane 
~Abbreviations used in this paper: FxlA, crude renal cortex fraction; HN, 
Heymann nephritis; HNAC, HN antigenic complex; GBM, glomemlar 
basement membrane; ID, immune deposit; pHN, passive Heymann ne- 
phritis; PLP, paraformaldehyde-lysine-periodate;  RAP, receptor-associ- 
ated protein; RAPI_st, NH2-tertmna186  amino acids of  RAP. 
(GBM) (6). The goal of our analyis ofpHN is to eventually 
develop  peptide-based  therapies  to  specifically  interfere 
with  ID  formation to provide a  curative therapy for this 
model of membranous glomerulopathy. 
In a series of investigations aimed at the identifcation of 
pHN antigens, we have used Abs eluted from glomeruli of 
diseased rats as the major tool, expecting that their specific- 
ities  could guide us to the target antigen(s) and eventually 
to  the  pathogenic  epitopes.  This  strategy  led  initially  to 
identification  of the  >515-kD  membrane  glycoprotein 
megalin/gp330 (7, 8) and then to the 44-kD receptor-asso- 
ciated  protein  (RAP;  9,  10)  formerly  called  C14  (11), 
which  are  associated together to form  the  Heymann ne- 
phritis antigenic complex (HNAC)  (9).  Search for patho- 
genic  epitopes on  HNAC  has  revealed one site that  was 
originally thought to be localized on megalin (12), but was 
subsequently found to reside within the 86 NH2-terminal 
amino acids  of RAP  (RAPl_86) (12).  Here, we further ex- 
ploit the specificity ofeluted glomerular Abs for the precise 
identification of the minimal antigenic target on RAP that 
is sufficient and competent for the induction of stable IDs. 
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Antibodies.  Anti-RAP Abs were prepared by intradermal im- 
munization  of rabbits  with 30  txg rtLAP from the  cDNA done 
C14,  as  described  (11).  IgG fractions were  prepared  on protein 
A-Sepharose 4B (Pharmacia, Uppsala, Sweden) and at~nity purified 
further on rKAP fusion protein coupled to a cyanogen bromide- 
Sepharose 4B column (Pharmacia)  (11).  Some IgG fractions were 
also affinity purified using a recombinant R.API_86 (12). 
Induction Of  pHN and Elution of Glomerular IgG.  PHN  was  in- 
duced by '-25 mg i.v. of anti-rRAP IgG into 200 g  male Lewis 
rats  (Charles River, Sulzfeld, Germany). Eluted IgG was prepared 
from the isolated glomeruli of 50 rat kidneys with 100 mM citric 
buffer,  pH  2.8  (7),  and  was  concentrated  on  protein  A-Seph- 
arose. The use of experimental animals was authorized by the Aus- 
trian Ministry of Science. 
Preparation of Immobilized  Overlapping Synthetic Peptides (SPOTs 
Assay).  The  SPOTs  technique allows simultaneous  solid phase 
synthesis of a large number ofpeptides that can be probed by im- 
munoblotting.  SPOTs membranes (Imperial Chemical Industries, 
Cambridge,  UK)  were  obtained  with  96  preformed  spots  in 
which a single amino acid was conjugated to the cellulose matrix 
as an anchoring site for peptides. NH2-terminally acetytated pep- 
tides were synthesized manually by a miniaturized Fmoc-chemistry 
Figure  1.  (A)  Sections  of  a 
SPOTs  membrane  containing  1l- 
iner  peptides  with  one  amino  acid 
overlap  representing  part  of  the 
RAP  amino  acid  sequence.  The 
membrane  was  immunoblotted 
with Ab  eluted  from the glomeruli 
of rats in which pHN was induced 
by lgG specific for rRAP.  This Ab 
labeled  specifically  two  clusters of 
spots, 34-40 and 43-46, but it failed 
to bind to spots, 25-33,  41  and  42, 
and 47-48.  (/3) In this interpretative 
table of the results of A, intensity of 
labeling of individual spots was arbi- 
trarily  scored  +,  ++,  and  ++ +, 
and expressed by shading. The con- 
sensus amino acid sequence  in each 
spot  is  marked  by  bold  print.  (C) 
Summary of results of SPOT experi- 
ments obtained  with Abs specific for 
the  glomerular  eluate  and  fbr 
RAP1-86. Both Abs bind to amino 
acids 40-53 and apparently spare the 
L amino acid residue at 45. 
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Peptide0 Related to Bindinu Sites for ID InducinmAbs 
Peptide 
Peptide 
Peptide 
RAP amino acid 
P31-44 
P46-53 
P31-53 
30  40  45  50  53 
1  1  1  1  1 
WEKAKRLHLSPVRLAELHSDLKI  QER 
WEKAKRLHL  S  PVRLAELHSDLKIQER 
WEKAKRLRLSPVRLAELHSDLKIQER 
Control P~Dtides 
Peptide  P55-46 
Peptide  P64-73 
Peptide  PI16-126 
~-~D~~  (amino  acids  55-64) 
KV~(~LDG~(~  (amino  acids  64-73) 
PI~T~KL~BI~,K  (amino  acids  116-126) 
Figure  2.  Composition  of  syn- 
I  thetic peptides of various regions of 
RAP used for the generation of  anti- 
bodies.  The  sequences  of the  pep- 
tides prepared are in bold print. 
protocol, following the manufacturer's instructions. RAP-derived 
peptides were  arranged as overlapping 11  mers with one amino 
acid offset,  covering the entire sequence of RAP or RAP1-86. 
Epitope  Mapping  by  Immunoblotting  on  SPOTs  Membranes. 
SPOTs  membranes were  immunoblotted with  affinity-purified 
Abs specific for RAP1-86  or with eluted glomerular IgG (11,  12). 
Membranes were developed and erased before reuse according to 
the  manufacturer's  instructions  (Imperial  Chemical  Industries). 
The amino acid sequences of Ab-binding domains were deduced 
from the common amino acid sequence shared by all labeled spots 
(Fig. 1). 
Design  and Production of Synthetic  Peptides.  Peptides  were  de- 
signed, two of which were extended by several amino acids to- 
wards the  NH  2 terminus of RAP beyond the region,  to  which 
eluted glomerular IgG bound in the SPOTs analysis (see  Fig. 2). 
Three  peptides  were  produced:  (a)  P31-53 (KAKRLHLSPVR.- 
LAELHSDLKIQE,  amino acids 31-53);  (b) P31-44 (KAKRLHL- 
SPVR.LAE,  amino  acids  31-44);  and  (c)  P46-53 (HSDLKIQE, 
amino acids  46-53).  As  controls,  the  irrelevant peptides  Ps5-64, 
P64-73,  and  PI16-126 from  outside  the  antigenic regions  of RAP 
were synthesized. Peptides were produced in an automatic pep- 
tide  synthesizer (model  430A;  Applied Biosystems,  Inc.,  Foster 
City,  CA).  Peptides were  purified to  >95% purity by reverse- 
phase  HPLC,  and their sequences were  analyzed in an Applied 
Biosystems gas phase sequencer at the Institute of Applied Micro- 
biology, University of Agriculture (Vienna, Austria). 
Preparation of Peptide-specific Abs.  Synthetic peptides were cou- 
pled to  a  multiple antigenic peptide-polylysine matrix  (13)  and 
rabbits were immunized with 2.5 mg i.d. of each synthetic pep- 
tide, followed by two boosts with  1 mg peptide,  each at 3  and 
6 wk.  Sera were  collected  at  weekly intervals from  the  second 
boost onwards. IgG fractions were purified on protein A-Sepharose 
4B  and further affinity purified on CNBr-Sepharose  coupled to 
the corresponding peptides (5-10 mg peptide/ml) as follows: 4 ml 
serum/rrd  affinity  adsorbent  were  circulated  for  12 h  at  4~ 
washed with 200 column volumes of PBS, and etuted with 20 mM 
gJycine-HC1 buffer, pH 2.8,  150 mM NaC1, 0.01% gelatin at 4~ 
Eluted IgG was neutralized with 1 M Tris-HC1 buffer, pH 8.0, dia- 
lyzed  against 4  liters  PBS,  and  concentrated with  Aquacide  II 
(Calbiochem, San Diego, CA) to 1-5 mg IgG/ml. P46-53 prepared 
as a multiple antigenic peptide or conjugated to KLH or BSA was 
not immunogenic in rabbits. P46_s3-specific IgG was therefore pre- 
pared by affinity purification of anti-RAP IgG on a  P46-s3 CNBr 
column and used in lieu of Abs raised against the synthetic pep- 
tide. 
Immunoblotting  of Peptide-spedfic Antibodies.  Rat  kidney  micro- 
villi were prepared as described (7),  and proteins were separated 
by  SDS-PAGE  and  transferred  onto  nitrocellulose membranes. 
Lysates  of isopropyl [3-D-thiogalactoside  (Sigma Chemical  Co., 
St.  Louis,  MO)~induced  Escherichia  coli producing  rRAP  (11) 
were  similarly transferred.  Immunoblotting was  performed with 
affinity-purified  antipeptide  Abs  (,~10  p~g/ml)  or  with  anti- 
Figure  3.  Antipeptide  Abs  specifically 
bind rRAP. Expression of a rRAP--GST 
fusion protein was induced in E. coil, the 
bacterial  lysate was  separated by  SDS- 
PAGE (lane A) and transferred onto nitro- 
cellulose membranes  and immunoblotted 
with irrelevant rabbit IgG as negative con- 
trol  (lane E), afflnity-purified antipeptide 
P31-53 IgG (lane B), affnity-pufified anti- 
peptide P31~.4 IgG  (lane C), and affinity- 
purified  IgG raised against RAPI~  6 (lane 
D). The arrow indicates RAP. 
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Figure 4.  Antipeptide Abs specifically recognize 
RAP  in microvillar fractions.  Isolated rat  tubular 
microviUi were separated by SDS-PAGE (lane A), 
transferred onto nitrocellulose membranes, and im- 
munoblotted with affinity-purified IgGs specific for 
P31-53 lgG (lane C), P31-44 IgG (lane D) and RAP  1_ 
86 (lane E); and negative control blotted with irrele- 
vant rabbit IgG (lane B). J SPOTs  Ammalf8 with  X~m  Sllocis  got  Slmat.hol:ic  Po~t:idem  n 
RAP amino acid 
Anti-P31-53 IgG 
Anti-P31-44 IgG 
Anti-P46-53 IgG 
30  40  45  50  55 
I  l  l  I  l 
WEKAKRLHL  S  ~-T.wmD~QZRDEL 
WEKAKRLHLS~LHSDLKIQERDEL 
WEKAKRLHL  S  PVRLAELHSD~QXRDEL 
Figure  5.  Results of SPOTs 
assays carried out with antipep- 
tide IgGs. Note that Abs to P31 53 
bind to amino acids 39-53, those 
raised to  P31-44 bound  only to 
amino  acids 39--43, and  those 
raised to  P4~-s3 bound to amino 
acids 47-53. 
PvAPI_86  IgG (3-5 ~g/ml; 12). As negative  controls, the primary 
Ab was omitted or replaced by irrelevant  rabbit  IgG, or blotting 
was performed on lysates of uninduced E.  coll. Immunoblotting 
was  also  performed  on  SPOTs  membranes,  as  previously  de- 
scribed. 
Immunofluorescence.  3 d after injection ofpeptide-specific IgGs, 
direct immunofluorescence was performed on semithin  1.5-btm 
frozen  sections  of rat  kidneys  fixed  with  paraformaldehyde- 
lysine-periodate (PLP; 14) and cut on an Ultracut ultramicrotome 
equipped with an FC 4 cryoattachment (P, eichert,  Vienna, Aus- 
tria). Sections were incubated with FITC-labeled goat anti-rabbit 
F(ab')2 fragments  (DAKO, Copenhagen, Denmark), followed by 
FITC rabbit anti-goat F(ab')2 (DAKO) to enhance the fluores- 
cence  signal. Micrographs were  taken  on an  Axiophot micro- 
scope  equipped  for  epifluorescence  (Zeiss, Oberkochen,  Ger- 
many). 
Immunohistochemistry on Isolated Basement  Membranes. Isolated  GBMs 
were prepared by incubation of 5-1~m unfixed cryostat sections of 
rat kidneys injected with anti-P3>s3 IgG with  1% Triton X-100 
in PBS, followed by 4% deoxycholate in distilled water for 1-3 h 
at 20~  (15). These cell-free  preparations  were processed for di- 
rect immunofluorescence, as described  above. Localization of IDs 
in similar  preparations  was performed by immunogold electron 
microscopy  as  described  (6). Briefly,  cell-free  sections  were 
quenched with  10% OVA in PBS and incubated with  1:100 di- 
luted  goat  anti-rabbit  IgG  conjugated to  10-rim gold particles 
(Amersham International, Amersham, UK) for 1 h at 20~  After 
five washes in PBS-10% OVA, samples were fixed with 2.5% glu- 
taraldehyde in 100 mM cacodylate buffer, pH 7.2, followed by 1% 
osmimn tetroxide in the same buffer and embedding in Epon 812. 
Electron Microscopy.  Samples  of renal  cortex  from  PLP-per- 
fused kidneys of rats injected with anti-P31_s3 Abs were postfixed 
in veronal acetate-buffered osmium, stained  en bloc with uranyl 
acetate, and processed for routine electron microscopy (6). 
BLAST&arches.  Online  BLAST  searches  were  performed 
via  the  National  Center  for Biotechnology Information at  the 
National  Institutes  of Health  (Bethesda,  MD).  PredictProtein 
(European Molecular Biology Laboratory, Heidelberg, Germany) 
was used for structural protein analysis (16). We use the term "ho- 
mology" as being identity plus conserved amino acid substitution. 
Results 
Anti-RAP Abs and Eluted  Glomerular  Abs  Bind Selectively 
to Two Adjacent Domains of RAP.  SPOTs  membranes  were 
prepared containing the primary sequence of RAPl_86 dis- 
assembled into 72 overlapping 11-meric synthetic peptides 
(Fig. 1, A  and B). This permitted simultaneous screening of 
all  peptides  for Ab-binding  sites  by immunoblotting  that 
was initially performed with IgG eluted from glomeruli of 
rats  injected  with  rRAP-specific  Abs.  Eluted  IgG specifi- 
cally labeled  two  clusters  of spots,  one  corresponding  to 
VRLAE (amino acids 40-44) and the second to HSDLKIQE 
(amino acids 46-53), which were separated by an L residue 
at amino acid 45  (Fig.  1, B and C). IgGs specific for rRAP 
and  RAP1_86  yielded  similar  results;  however,  both  IgGs 
bound also to an additional P residue at amino acid 39 (Fig. 
1  C).  No  labeling  was  observed  in  control  experiments 
with irrelevant rabbit IgG or without primary Ab (data not 
shown). 
These  results  indicate  that the  minimal  binding sites  on 
RAP of the most relevant Ab in this study, i.e.,  the eluted 
glomerular IgG, comprised a region of 14 amino acids with 
one intervening L residue. The accuracy of the NH2-termi- 
nal  border  of the  first  Ab-binding  region  was  limited  by 
variation  of +  1 amino  acid in repeated  immunoblots  on 
multiple SPOTs membranes. 
Antipeptide Antibodies React Specifically with RAP.  Two syn- 
thetic peptides  were designated P31~4 and P46-53 according 
to their  amino  acid composition.  P31-44  was  extended  be- 
yond the binding region of eluted glomemlar IgG by nine 
amino acids towards the NH2 terminus of RAP to account 
for the variability of this border in the SPOTs assays. In ad- 
dition, P31-53, which covered both binding regions of eluted 
IgG, was synthesized (Fig. 2). Rabbit Abs specific for these 
peptides were prepared and affinity purified on CNBr pep- 
tide columns. 
All  antipeptide  IgGs  specifically  and  strongly  reacted 
with RAP by immunoblotting on transfers  of rRAP  (Fig. 
3)  or on isolated microvillar fractions  (Fig.  4).  On SPOTs 
membranes,  anti-P3>44  IgG  specifically  labeled  PVRLAE 
(amino  acids  39--44),  and  anti-P46_s3  IgG bound  to  SDL- 
KIQE (amino acids 47-53).  IgG raised against P31-53 bound 
to PVRLAELHSDLKIQE (amino acids 39-53) but not to 
amino  acids  31-38  (Fig.  5).  In  control  experiments,  Abs 
raised to peptides  distant  from the  NH  2 terminus  of RAP 
bound only to their respective antigenic peptides  (data not 
shown). These data provide evidence that Abs raised against 
synthetic peptides  selectively bound to their respective  se- 
quences  on  RAP  and  mirrored  the  binding  sites  of IgG 
eluted from glomeruli. 
Antibodies Specific  for Peptide P31-s.3 Induce IDs  That Firmly 
Attach to the GBM.  Abs  produced  against  peptides  P31-aa 
and P4r  failed to induce IDs at 3  and 6  d  after injection 
into  rats  (data  not  shown).  By contrast,  fine  granular  IDs 
were observed in the peripheral capillary walls ofglomeruli 
after injection of anti-P31_s3  IgG (Fig. 6), in a pattern typi- 
cal for HN.  Some  IgG was  also  detected  within  the  me- 
sangium.  The glomerular pattern  of IDs was confirmed by 
2010  Heymann Nephritis  Induced by Peptides Figure  6.  Affinity-purified 
IgG  specific for  peptide ])31-53 
produces IDs 3 d after intrave- 
nous injection. IDs are visualized 
by  direct immunofluorescence 
on semithin 1.5-~m frozen sec- 
tions. There  are  numerous fine 
granular  IDs  in  the  peripheral 
glomerular capillary walls. The 
mesangiurn is  also labeled in  a 
granular  pattern  (M).  Several 
large  intracellular  vacuoles  of 
glomerttlar epithelial cells (arrow- 
heads)  contain  rabbit  IgG. 
￿  1200. 
electron microscopy, which revealed small deposits prima- 
rily within  clathrin-coated pits  at the base of the foot pro- 
cesses ofpodocytes (Fig. 7). 
Unfixed kidney sections of rats  injected with anti-P31_53 
IgG were extracted with detergents to remove cellular ma- 
terial.  By  direct  immunofluorescence,  granular  IDs  con- 
taining rabbit IgG were observed to adhere to the cell-free 
GBMs of glomerular capillaries  (Fig.  8)  similar in size and 
distribution  to  IDs  in  unextracted  sections.  By immuno- 
electron microscopy of isolated GBMs,  IDs were observed 
in  the  lamina  rara  externa  of the  GBM  that  were  specifi- 
cally labeled by anti-rabbit IgG-gold conjugate (Fig. 9). 
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These  results  indicate  that  IgGs specific  for P31-s3 form 
small  IDs in peripheral  glomerular  capillary loops and that 
these IDs are firmly attached to the GBMs.  Thus, this pep- 
tide-specific  Ab  is  able  to  generate  small  IDs  similar  to 
those observed in pHN induced by IgGs specific for rRAP 
or RAP1_86  (11,  12). 
Predictions of  Homologies and Structure of the P31-s3.  P31-53  was 
found to contain twice a putative RT-1B 1 MHC  class  II- 
binding motif,  S x  x  x  x  x  E  (Fig.  10),  thought to be im- 
portant for generation of Abs in Lewis rats  (17).  Search for 
sequence  similarities  revealed  no  other  significant  resem- 
blance of  P31_s3 to other rat proteins. Predictions of second- Figure 7.  Gallery of electron micrographs oflDs in- 
duced by anti-P31_53--specific  IgG. The IDs are local- 
ized within clathrin-coated pits (cp) and under the slit 
diaphragms (sd). ￿ 
ary structure  with  70%  certainty  (16)  indicated that  P31-53 
contains two helical regions at amino acids 31-35  and 41- 
53 connected by a short loop ranging from amino acids 36 
to 40 (Fig. 11). 
Discussion 
Binding  of  antibodies  in  situ  to  specific  epitopes  on 
HNAC,  a  complex  of RAP  and  megahn/gp330  (9,  18), 
triggers the  formation  of persistent  IDs  in  the  GBM  (6). 
We and others have observed that Abs raised against rRAP 
form  IDs after injection into  rats  (11,  19).  We had previ- 
ously  identified  a  single  ID-forming  epitope  at  the  NH2 
terminus ofIKAP (KAP~_s6)  (12) by the expression of a se- 
ries of RAP cDNA deletion clones, raising of specific Abs, 
and  probing  of  their  ability  to  induce  glomerular  IDs. 
Here,  we precisely determine the  minimal amino  acid se- 
quence  on  RAPI4 6  that  is  required  for  the  binding  of 
Figure  8.  Immune  deposits induced  by anti-P3~ 53 
IgG firmly adhere to isolated GBMs. Cryostat sections 
of unfixed kidneys of rats injected with anti-P31_53 IgG 
were extracted with detergents to remove the cellular 
material and to leave behind only cell-free basement 
membranes. IDs were visualized  by direct immunoflu- 
orescence in glomerular capillary  loops as fine granular 
deposits that are particularly well resolved in sections 
grazing through capillary  loops (arrowheads).  ￿  1,200. 
2012  Heymann Nephritis Induced by Peptides Figure 9.  Localization  oflDs in a preparation of isolated GBMs by di- 
rect immunogold immunoelectron microscopy. Small clusters of gold 
particles (arrowheads)  are located on the external  side of the isolated GBM 
of  a rat that was injected  3 d before  death with anti-P31_s3 IgG. M, mesan- 
gial matrix; US, urinary  space. X65,000. 
eluted  glomerular  IgG  by  mapping  of IgG-binding  do- 
main(s)  on overlapping synthetic peptides. In a second step, 
synthetic peptides that duplicated the Ab-binding domains 
were produced,  and  specific Abs  were  raised and  probed 
for their capacity to induce stable glomerular IDs. 
Mapping of binding sites of etuted Abs on a large num- 
ber of RAPl_86-derived synthetic peptides was performed 
by SPOTs  assays. The results provided evidence for two 
adjacent Ab-binding  domains  within  the  sequences  VR- 
LAELH  (amino acids  40--44)  and HSDLKIQE (amino ac- 
ids 46-53), with an apparent inaccuracy of +  1 amino acid 
at the NH2-terminal border of the first binding site.  These 
findings raised the possibili  W that RAP amino acids  40-53 
were involved in ID formation in vivo and that appropriate 
peptide-specific Abs  could  induce  IDs.  At  first,  peptides 
P31-44 and P46-s3 were synthesized, and specific rabbit Abs 
were prepared which,  however, failed to form IDs when 
injected into rats.  Therefore, a large peptide spanning both 
P31~t4 and P46-53 was designed and designated P31-53- Intra- 
venous injection of  Abs raised against  this peptide promptly 
induced small IDs in the peripheral capillary walls of glom- 
eruli. Moreover, these IDs strongly adhered to the GBM in 
cell-free preparations of GBMs. Thus, in most respects, IDs 
produced by injection of anti-P3i_53 IgG  were  similar  to 
those induced by conventional Abs (6). 
These  data  indicate  that  anti-P31_s3 IgG  binds  in  vitro 
and in vivo to the  same  amino acid sequence of RAP  as 
Abs eluted from glomeruli of rats with pHN. Intriguingly, 
Abs  raised  against  P31--44 and  P46-s3 failed to  produce  IDs 
when injected into  rats.  It is possible  that  P31-53 acts  as  a 
composite peptide that mimics a natural structural epitope 
by simultaneously presenting two linked antigenic peptides 
to the immune system. Thus, while Abs raised against  the 
composite peptide bind in vivo to the native protein, Abs 
raised against individual smaller peptides bind to their re- 
spective  amino  acid  sequences  only in  vitro  in  unfolded 
proteins. A  similar situation was recently observed for the 
proliferating  cell  nuclear  antigen  in  lupus  erythematosus 
(20). Abs specific for individual synthetic peptides modeled 
after immunogenic  domains  failed  to  bind  in  vivo.  Abs 
raised against  a  dimer of these peptides,  however, readily 
bound to their nuclear antigen in vivo, presumably because 
this composite peptide antigen resembled the correspond- 
ing conformation-dependent natural epitope. It remains to 
be seen to which extent the structural predictions of a he- 
lix-loop-helix motif in the region of the P31-s3 peptide are 
related to the topography of this epitope on RAP. 
HN is characterized by relatively large IDs and by pro- 
teinuria.  Although large amounts of Ab  specific for P31-53 
were injected into rats, the IDs obtained were considerably 
smaller than  those  induced by conventional Abs,  such  as 
antimegalin/gp330 IgG (6, 21). h  is possible that anti-P31_53 
IgG serves  only as nidus for ID formation, and that addi- 
tional Abs directed against  epitopes on megalin bind subse- 
quently. We have provided evidence that antimegalin Abs 
without reactivity to RAP induce IDs (21), and one epitope 
on megalin was recently identified on the fifth cystine-rich 
repeat of the second LDL receptor-like domain of megalin 
(22).  Thus, while the RAP epitope identified in this study 
provides a single  nidus for the formation of an initial ID, it 
is clear that additional epitopes on megalin must be opera- 
tive to yield IDs of the large sizes typically found in passive 
and active HN. Lack of proteinufia after injection of anti- 
P31-53 IgG is presumably caused by the absence of  C5b-9-acti- 
rating Abs specific for glycolipids that were recently identi- 
fied as components ofanti-FxlA IgG (23). 
In a next step, it will be of  interest to attempt to produce 
active HN by immunization  of Lewis rats  with  synthetic 
peptides, which may be facilitated by two putative MHC 
class II peptide--binding motifs specific for Lewis rats  (17) 
within  P31-53. Further  on,  attempts  to  interfere with  the 
immunologic basis  of the disease  by use of synthetic pep- 
tides will be possible. One example indicating the feasibil- 
ity of this approach is derived from studies on experimental 
murine interstitial nephritis (24), which was ameliorated by 
specific synthetic peptides. 
I  RAP amino  acid  30  40  45  50 
I  L  i  I 
Peptide  P31-53  WE~S~DLKIQER 
f  i  i  f 
IMHC Class  II Motif RT-IB  1  SxxxxxE  SxxxxxE 
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Figure  10.  Homolgy searches 
with  online BLAST revealed that 
the Lewis rat MHC class II-binding 
motif S x x x x x E is contained 
twice within P31-s3. Figure 11.  Predicted secondary structure by 
the ProteinPredict program (70% accuracy) of 
the P31->3 region by the EMBL-PredictProtein 
program. As indicated by cylinders, this region 
comprises two helical structures connected by a 
short loop. A third helix distant to the Ab-bind- 
ing region and extending towards the COOH 
terminus of RAP is depicted. 
Collectively, the  results  of this  study provide  evidence 
for a presumably structural epitope on RAP that is respon- 
sible for  the  formation  of subepithelial IDs  in  pHN  and 
spans  14  amino  acids. These  findings are also the first ex- 
ample of induction of glomerular IDs with Abs specific for 
synthetic peptides modeled after natural Ab-binding sites. 
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